Drug reference

selpercatinib

RET kinase inhibitor, kinase inhibitor · antineoplastic, targeted therapy

RET kinase inhibitor, kinase inhibitorantineoplastic, targeted therapy

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

FDA category + note

Top interactionssee all 12 →

AbarelixSevereDatabaseDDInter
AbirateroneSevereDatabaseDDInter
AdenosineSevereDatabaseDDInter
AlfuzosinSevereDatabaseDDInter

Mechanism

Selective RET kinase inhibitor.

Indications

RET-driven medullary thyroid carcinomas that progress despite surgerysystemic therapy of thyroid cancers with RET driver mutations (papillary cancers with RET fusion genes and medullary cancers with RET point mutations)metastatic RET fusion–positive NSCLCadvanced or metastatic RET-mutant medullary thyroid cancer

Pharmacokinetics

Half-life

32 h

Metabolism

CYP3A4 (predominantly)

Side effects

Serious

hepatotoxicity
hypertension
QTc prolongation
impaired wound healing
tumor lysis syndrome

Pregnancy & lactation

Pregnancy

Drug interactions

Abarelix

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Abiraterone

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Adenosine

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Alfuzosin

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Alimemazine

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Aluminum Hydroxide

Severe

Database

Drug interaction classified as: absorption

Source: DDInter

Amiodarone

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Amisulpride

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Amitriptyline

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Amoxapine

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Amprenavir

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Anagrelide

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Related guidelines

Breast cancer

ESMO · Oncology · 2024

Breast cancer

ICMR · Oncology · 2022

Hypothyroidism in adults

ITS · Endocrinology · 2021

Cervical cancer screening and management

ICMR · Oncology · 2022

Tobacco-related cancer prevention

ICMR · Oncology · 2021

Ask House about selpercatinib

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team